Plain-English translation of NCT06917664 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a medication called can help improve a leaky heart valve (mitral regurgitation) in patients who have coronary artery disease and are undergoing bypass surgery. About 220 people will take part. Some will receive bypass surgery alone, while others will receive bypass surgery followed by daily doses of this medication to see if it reduces the valve leakage more effectively.
After bypass surgery, some patients develop or have worsening leakiness in their mitral valve, which can cause heart problems over time. Researchers want to find out if this medication can help prevent or reduce this leakiness, potentially improving long-term heart health and quality of life.
You likely qualify if…
You likely don't qualify if…
If you qualify and join this trial, you will have bypass surgery as part of your treatment plan. After surgery, you will be randomly assigned to either receive the new medication () daily or not receive it. You will visit the hospital for follow-up appointments where doctors will monitor your heart with ultrasounds and blood tests to see how well your mitral valve is working over time.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
China